Log in

Seres Therapeutics Stock Forecast, Price & News

+0.15 (+0.59 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $25.42
50-Day Range
MA: $31.53
52-Week Range
Now: $25.42
Volume879,791 shs
Average Volume1.15 million shs
Market Capitalization$2.32 billion
P/E RatioN/A
Dividend YieldN/A
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MCRB



Sales & Book Value

Annual Sales$34.51 million
Book Value$2.06 per share


Net Income$-70,280,000.00
Net Margins-385.22%


Market Cap$2.32 billion
Next Earnings Date3/1/2021 (Estimated)
+0.15 (+0.59 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

How has Seres Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MCRB stock has increased by 862.9% and is now trading at $25.42.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Seres Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Seres Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Seres Therapeutics?

Wall Street analysts have given Seres Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seres Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Seres Therapeutics

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its quarterly earnings data on Monday, November, 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.12. Seres Therapeutics had a negative return on equity of 2,867.98% and a negative net margin of 385.22%.
View Seres Therapeutics' earnings history

What price target have analysts set for MCRB?

6 Wall Street analysts have issued twelve-month price targets for Seres Therapeutics' shares. Their forecasts range from $27.50 to $49.00. On average, they expect Seres Therapeutics' stock price to reach $37.75 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price.
View analysts' price targets for Seres Therapeutics

Who are some of Seres Therapeutics' key competitors?

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), 1877 (JUNO), NVIDIA (NVDA), The Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:
  • Mr. Eric D. Shaff M.B.A., Pres, CEO & Director (Age 44, Pay $801.4k)
  • Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 45, Pay $530.4k)
  • Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 65, Pay $597.7k)
  • Mr. Marcus Chapman, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 49)
  • Dr. David S. Ege Ph.D., Exec. VP & Chief Technology Officer
  • Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications
  • Mr. Jeff York, VP of HR
  • Ms. Jayne M. Gansler, Exec. VP & Chief People Officer
  • Dr. John G. Aunins, Sr. Advisor (Age 59)
  • Mr. James R. Weston, Sr. VP of Regulatory Affairs

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (16.12%), BlackRock Inc. (7.90%), Nikko Asset Management Americas Inc. (7.25%), Federated Hermes Inc. (3.66%), State Street Corp (1.21%) and Charles Schwab Investment Management Inc. (0.38%). Company insiders that own Seres Therapeutics stock include Eric D Shaff, John G Aunins, Marcus Chapman, Noubar Afeyan and Thomas Desrosier.
View institutional ownership trends for Seres Therapeutics

Which major investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., JPMorgan Chase & Co., ARK Investment Management LLC, Charles Schwab Investment Management Inc., LPL Financial LLC, Squarepoint Ops LLC, KBC Group NV, and Morgan Stanley.
View insider buying and selling activity for Seres Therapeutics

Which major investors are buying Seres Therapeutics stock?

MCRB stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Lord Abbett & CO. LLC, Point72 Asset Management L.P., State Street Corp, AQR Capital Management LLC, Cubist Systematic Strategies LLC, and Victory Capital Management Inc..
View insider buying and selling activity for Seres Therapeutics

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $25.42.

How big of a company is Seres Therapeutics?

Seres Therapeutics has a market capitalization of $2.32 billion and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Seres Therapeutics employs 108 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.